Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Roswell Park Cancer Institute Stories

2014-02-26 23:00:48

In the largest study to link secondhand smoke exposure to adverse fetal impacts, researchers report that secondhand smoking may lead to pregnancy loss, including miscarriage, stillbirth and tubal ectopic pregnancy. Buffalo, NY (PRWEB) February 26, 2014 Secondhand smoking is linked with pregnancy loss, including miscarriage, stillbirth and tubal ectopic pregnancy, according to new research from scientists at Roswell Park Cancer Institute (RPCI) and the University at Buffalo (UB). The study...

2014-02-11 08:31:08

WESTLAKE, Ohio, Feb. 11, 2014 /PRNewswire/ -- GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations. (Logo: http://photos.prnewswire.com/prnh/20140204/CL58248LOGO) "The challenges of translating the vast amounts of data from next-generation sequencing into a resource that can be easily and...

2014-01-30 23:03:55

In the second whole-genome sequencing study ever conducted in bladder cancer, a Roswell Park-led team observed two distinct patterns of aberrations, and identified a potential target for therapy. Buffalo, NY (PRWEB) January 30, 2014 In the first whole-genome analysis conducted through the Roswell Park Cancer Institute (RPCI) Center for Personalized Medicine, researchers report that invasive bladder cancers demonstrate two distinct patterns of genetic alteration, one of which may result...

2014-01-09 12:26:51

NEW YORK, Jan. 9, 2014 /PRNewswire/ -- The New York Genome Center (NYGC) announced that New York State Governor Andrew M. Cuomo proposed in his State of the State address Wednesday afternoon a $105 million partnership between the NYGC and the University at Buffalo's Center for Computational Research, enabling genetic discoveries that will potentially save lives by transforming how health care impacts patients. Governor Cuomo's commitment to vastly enhancing the genomic medicine...

2013-12-13 12:22:05

CTG's innovative approach to using predictive analytics for personalized medicine is recognized BUFFALO, N.Y., Dec. 13, 2013 /PRNewswire/ -- CTG (NASDAQ: CTG), an IT solutions and services company, announced today that it placed 132, putting it in the top third, on the 25(th) annual InformationWeek 500 list of the country's most innovative users of business technology. To qualify for the InformationWeek 500 list, companies with $250 million or more in annual revenue were invited to...

2013-12-12 23:01:48

A study led by Roswell Park Cancer Institute's Maciej Gonieicz found that e-cigarettes emit significant amounts of nicotine, but not any substantial amounts of carbon monoxide or other toxic compounds. Buffalo, NY (PRWEB) December 12, 2013 Electronic cigarettes, when used indoors, may involuntarily expose non-users to nicotine, according to a study led by Maciej Goniewicz, PhD, PharmD, of Roswell Park Cancer Institute (RPCI) and published by the journal Nicotine and Tobacco Research....

2013-11-19 12:29:53

Study May Help Millions Diagnosed and Treated for Cancer Each Year BOSTON, Nov. 19, 2013 /PRNewswire/ -- A group of the nation's leading cancer institutions is set to release the findings of a two-year study focused on nutrition and food preferences among patients receiving cancer treatment on Nov. 19 at Boston's TD Garden. In addition, the newly-created Cancer Nutrition Consortium will make its debut as a part of the two-day event. The group was formed to look at the issue...

2013-10-28 08:30:11

BUFFALO, N.Y., Oct. 28, 2013 /PRNewswire/ -- Kinex Pharmaceuticals today announced that the first patient has been dosed in its Phase Ib Oraxol study. Oraxol allows for oral delivery of paclitaxel when combined with Hanmi Pharmaceutical's absorption enhancer, HM30181A. This trial is being conducted in the United States. Oraxol is in PII studies in Korea and will commence a PI in New Zealand in 2014. Kinex has global development and commercialization rights for Oraxol, excluding...

2013-10-24 23:04:39

Reportbuyer.com just published a new market research report: Nonmelanomatous Skin Cancer Global Clinical Trials Review, H2, 2013 (PRWEB) October 24, 2013 Summary GlobalData's clinical trial report, “Nonmelanomatous Skin Cancer Global Clinical Trials Review, H2, 2013" provides data on the Nonmelanomatous Skin Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nonmelanomatous Skin Cancer. It includes an overview...

2013-10-24 16:25:50

IMRT use is 2 1/2 times greater when self-referral's financial incentives are involved FAIRFAX, Va., Oct. 24, 2013 /PRNewswire-USNewswire/ -- A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity- modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of...